{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-015546","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.494425+00:00","generated_at":"2026-06-18T23:09:38.806869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nektar reports Q4 2022 net loss $59.7M; cash $505M, runway through mid-2025","bullets":["Q4 2022 revenue $22.0M (down from $25.0M YoY); full-year revenue $92.1M (down from $101.9M).","Q4 net loss $59.7M ($0.32 loss per share) vs $145.6M ($0.79) in Q4 2021; full-year net loss $368.2M ($1.97) vs $523.8M ($2.86).","Cash and investments $505.0M at Dec 31, 2022, down from $798.8M; CEO expects runway through at least mid-2025 with additional cost cuts.","R&D expense fell to $34.7M in Q4 (from $99.6M) due to wind down of bempegaldesleukin program; restructuring costs $11.6M in Q4.","On Feb 23, 2023, announced Phase 2 topline data for rezpegaldesleukin in SLE; no Q4 earnings call held."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-015546","json":"https://secwatch.observer/filing/0001213900-23-015546.json","markdown":"https://secwatch.observer/filing/0001213900-23-015546.md","text":"https://secwatch.observer/filing/0001213900-23-015546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/0001213900-23-015546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/ea174444-8k_nektartherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:09:38.806869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05e21ee3890ed934054c3e0d3ee68e50874c0a3c","claim":"NEKTAR THERAPEUTICS reported the quarter and year ended December 31, 2022 results: revenue Revenue in the fourth quarter of 2022 was $22.0 million, net income Net loss for the fourth quarter of 2022 was $59.7 million, EPS $0.32 basic and diluted loss per share.","evidence_excerpt":"On February 28, 2023, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023015546/0001213900-23-015546-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"Revenue in the fourth quarter of 2022 was $22.0 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $59.7 million"},{"label":"EPS","value":"$0.32 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}